Navigator Medicines, NAV-240, NAV-242, Hidradenitis Suppurativa, HS, TNFα, OX40L, Bispecific Antibody, Bispecific Therapeutics, MAINSAIL, Phase 2a, Phase 1, EADV 2026, Dermatology,

SAN MATEO, Calif. — September 29, 2026 Navigator Medicines announced new clinical and translational data from its NAV-240 and...